In a study published in Scientific Reports, researchers engineer long-lasting GLP-1 receptor agonists by fusing GLP-1 with an HSA-binding protein. These chimeric molecules show promise for the treatment of type 2 diabetes due to their stability, functionality, and high affinity for the GLP-1 receptor and human serum albumin.
Novel GLP-1 receptor agonists offer hope for long-lasting diabetes treatment
- Post author:
- Post published:October 22, 2023
- Post category:uncategorized